Heritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Authors:
- Yu. V. DinikinaYDYu. V. Dinikina
- O. G. ZheludkovaOZO. G. Zheludkova
- P. A. MaizengerPMP. A. Maizenger
- I. L. NikitinaINI. L. Nikitina
- I. V. BezyazychnayaIBI. V. Bezyazychnaya
- G. G. RaduleskuGRG. G. Radulesku
- I. A. LeonovaILI. A. Leonova
- T. V. KosenkovaTKT. V. Kosenkova
- G. I. ObraztsovaGOG. I. Obraztsova
- E. B. BashninaEBE. B. Bashnina
- M. B. BelogurovaMBM. B. Belogurova
Open Access
- 8 September 2024
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 91-101
Abstract
Today, the contribution of hereditary tumor syndromes to the development of cancer in children is obvious, which determines the need for screening programs and selection of the most effective methods of anticancer therapy. One of the most aggressive hereditary tumor syndromes is heritable TP53-related cancer syndrome (hTP53rc, formerly known as Li–Fraumeni syndrome), characterized by a high risk, early onset and recurrent cases of malignant neoplasms in one patient. The article describes current data on hTP53rc syndrome and the features of its clinical course, and provides international recommendations for monitoring and cancer screening in pediatric patients with hTP53rc syndrome. As a clinical observation, we present an analysis of the registry of patients with relapsed and refractory forms of medulloblastoma (n = 241) with the assessment of its incidence in cases of germline mutations in the TP53 gene with the description of their medical history and the influence of this genetic event on the outcomes. The results of our study, as well as data from international literature, indicate unfavorable prognosis in tumors, including medulloblastoma, in patients with hTP53rc syndrome, however, such factors as early screening, surveillance and early and adequate therapy can help to increase their life expectancy. The study was approved by the Independent Ethics Committee and the Scientific Council of the Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation.Keywords
This publication has 35 references indexed in Scilit:
- Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other featuresFamilial Cancer, 2021
- Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variantsHuman Mutation, 2020
- Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry studyCancer Medicine, 2020
- Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndromeBreast Cancer Research and Treatment, 2020
- Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyAmerican Journal of Medical Genetics Part A, 2017
- Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI examsPediatric Radiology, 2016
- Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection toolEuropean Journal of Medical Genetics, 2016
- Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencingEuropean Journal of Pediatrics, 2015
- Surveillance for hereditary cancer: Does the benefit outweigh the psychological burden?—A systematic reviewCritical Reviews in Oncology/Hematology, 2012
- Reassessment of theTP53 mutation database in human disease by data mining with a library ofTP53 missense mutationsHuman Mutation, 2004